ReviewSeminars in fetal & neonatal medicine2018
Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.
Review in Seminars in fetal & neonatal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 51 citations in OpenAlex.
- The clinical utility of paracetamol serum concentration monitoring for patent ductus arteriosus treatment in preterm infants.Journal of perinatology : official journal of the California Perinatal Association · 2026Article
- Caffeine-associated reduction in patent ductus arteriosus is mediated in part by adenosine receptor antagonism.American journal of physiology. Heart and circulatory physiology · 2025Article
- Genetics of Congenital Heart Disease: A Narrative Review of Challenges and Strategies in Identifying Novel Genes.Cureus · 2025Review
- Pharmacologic Management of Patent Ductus Arteriosus in the Neonatal Intensive Care Unit: A Retrospective Study.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Review
- Review of Precision Medicine and Diagnosis of Neonatal Illness.Diagnostics (Basel, Switzerland) · 2025Review
- Patent Ductus Arteriosus in Extremely Preterm Infants: Update on Current Diagnostic and Treatment Options.Current treatment options in cardiovascular medicine · 2025Review
- Loss-of-function of RNA-binding protein PRRC2B causes translational defects and congenital cardiovascular malformation.medRxiv : the preprint server for health sciences · 2024Article
- Ductus Arteriosus in Fetal and Perinatal Life.Journal of cardiovascular development and disease · 2024Review
- A harmful MYH11 variant detected in a family with thoracic aortic dissection and patent ductus arteriosus.Forensic science, medicine, and pathology · 2024Article
- Clinical and echocardiography predictors of response to first-line acetaminophen treatment in preterm infants with hemodynamically significant patent ductus arteriosus.Journal of perinatology : official journal of the California Perinatal Association · 2024Article
- Association between endotypes of prematurity and pharmacological closure of patent ductus arteriosus: A systematic review and meta-analysis.Frontiers in pediatrics · 2023Article
- The Association of Patent Ductus Arteriosus with Inflammation: A Narrative Review of the Role of Inflammatory Biomarkers and Treatment Strategy in Premature Infants.International journal of molecular sciences · 2022Review
- Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider.Journal of the American Heart Association · 2022Review
- Identification ofDiagnostics (Basel, Switzerland) · 2022Article
- Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.Developmental dynamics : an official publication of the American Association of Anatomists · 2022Review
- Transcriptome Analysis Reveals Differential Gene Expression between the Closing Ductus Arteriosus and the Patent Ductus Arteriosus in Humans.Journal of cardiovascular development and disease · 2021Article
- Patent Ductus Arteriosus of the Preterm Infant.Pediatrics · 2020Review
- Early Urinary Metabolomics in Patent Ductus Arteriosus Anticipates the Fate: Preliminary Data.Frontiers in pediatrics · 2020Article
- Molecular and Mechanical Mechanisms Regulating Ductus Arteriosus Closure in Preterm Infants.Frontiers in pediatrics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Patent ductus arteriosus (PDA) is a frequent, complex, and difficult to treat clinical syndrome among preterm infants in the neonatal intensive care unit. In addition to known clinical risk factors, there are emerging data about genetic predisposition to PDA in both animal and human models. Clinical response and toxicity from drugs used to treat PDA are highly variable. Developmental and genetic aspects of pharmacokinetics and pharmacodynamics influence exposure and response to pharmacologic therapies. Given the variable efficacy and toxicity of known drug therapies, novel therapeutic targets for PDA treatment offer the promise of precision medicine. This review addresses the known genetic contributions to prolonged ductal patency, variability in response to drug therapy for PDA, and potential novel drug targets for future PDA treatment discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.